Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates

Keyphrases

• Intravenous Bisphosphonates 100%
• Osteonecrosis of the Jaw 100%
• Osteoporotic Patients 100%
• Bisphosphonates 66%
• Osteoporosis 50%
• Older Adults 16%
• Risk Factors 16%
• Survival Analysis 16%
• Osteoporosis Treatment 16%
• National Sample 16%
• Medicare Beneficiaries 16%
• Inflammatory Conditions 16%
• Disease Factor 16%
• Total Dose 16%
• Multivariable 16%
• Potential Confounders 16%
• Intravenous Infusion 16%
• Risk Profile 16%
• Bone Disease 16%
• Patients with Cancer 16%
• Metabolic Bone Disease 16%
• Bisphosphonate Use 16%
• Log-rank Test 16%
• Sex Type 16%
• Population-based Cohort 16%
• Absolute Risk 16%
• Cox Proportional Hazards Regression 16%
• Bisphosphonate Therapy 16%
• Toxicity Outcomes 16%
• Clinical Scenarios 16%
• Risk-benefit Ratio 16%
• Facial Bones 16%

Medicine and Dentistry

• Osteoporosis 100%
• Osteonecrosis of the Jaw 100%
• Bisphosphonate 100%
• Jaw 40%
• Proportional Hazards Model 20%
• Malignant Neoplasm 10%
• Medicare 10%
• Serositis 10%
• Intravenous Drug Administration 10%
• Metabolic Bone Disease 10%
• Risk-Benefit Ratio 10%
• Log Rank Test 10%
• Facial Bone 10%
• Bone Disease 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Bisphosphonic Acid Derivative 100%
• Jaw Osteonecrosis 100%
• Malignant Neoplasm 20%
• Inflammation 10%
• Metabolic Bone Disease 10%
• Bone Disease 10%